GR1002847B - Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως - Google Patents

Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως

Info

Publication number
GR1002847B
GR1002847B GR970100172A GR970100172A GR1002847B GR 1002847 B GR1002847 B GR 1002847B GR 970100172 A GR970100172 A GR 970100172A GR 970100172 A GR970100172 A GR 970100172A GR 1002847 B GR1002847 B GR 1002847B
Authority
GR
Greece
Prior art keywords
micropostol
erection
problems related
therapeutic
acid
Prior art date
Application number
GR970100172A
Other languages
English (en)
Inventor
Original Assignee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by filed Critical
Publication of GR1002847B publication Critical patent/GR1002847B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GR970100172A 1997-05-06 1997-05-06 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως GR1002847B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR97100172 1997-05-06

Publications (1)

Publication Number Publication Date
GR1002847B true GR1002847B (el) 1998-01-27

Family

ID=10942965

Family Applications (1)

Application Number Title Priority Date Filing Date
GR970100172A GR1002847B (el) 1997-05-06 1997-05-06 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως

Country Status (10)

Country Link
US (2) US6210343B1 (el)
EP (1) EP0980245B1 (el)
JP (1) JP2001525803A (el)
AT (1) ATE261307T1 (el)
AU (1) AU6848098A (el)
DE (2) DE69822295T2 (el)
ES (1) ES2216279T3 (el)
GR (1) GR1002847B (el)
PT (1) PT980245E (el)
WO (1) WO1998050039A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US7087240B1 (en) * 1998-06-25 2006-08-08 Lavipharm Laboratories Inc. Device and method for the treatment of erectile dysfunction
GR1003199B (el) 1998-08-14 1999-09-01 Χρηση της μισοπροστολης ή και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση της σεξουαλικης δυσλειτουργιας στις γυναικες
US6825234B2 (en) 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
AU3713600A (en) 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
AU2003208309A1 (en) * 2002-02-22 2003-09-09 Hans Gregersen Method and apparatus for investigating force-deformation properties in muscles in walls of bodily hollow systems
US7037257B1 (en) * 2002-08-22 2006-05-02 Koenig J Frank Erectile dysfuction treatments comprising momentary vacuum therapy alone or with medications
US8287474B1 (en) 2002-08-22 2012-10-16 Koenig J Frank Method and apparatus for noninvasively increasing whole body blood flow and noninvasive physical exercise of limbs from the outside and from within the limb to treat diseases throughout the body
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20050255161A1 (en) * 2004-05-10 2005-11-17 Servet Buyuktimkin Method for the long term stabilization of labile compounds at room temperature in pharmaceutical preparations containing water
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
WO2006133048A2 (en) * 2005-06-03 2006-12-14 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
JP2010095454A (ja) * 2008-10-14 2010-04-30 Cyclochem:Kk 抗菌組成物
US20100184722A1 (en) * 2008-12-19 2010-07-22 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
RU2428933C1 (ru) * 2010-02-19 2011-09-20 Государственное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет имени акад. И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ определения индекса функциональной достаточности артериального кровенаполнения кавернозной ткани по результатам ультрасонографии полового члена
RU2444989C1 (ru) * 2010-09-27 2012-03-20 Государственное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России) Способ диагностики васкулогенной эректильной дисфункции
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
IT201600119871A1 (it) * 2016-11-25 2018-05-25 Sabatino Russo Uso dell’associazione di inibitori della fosfodiesterasi 5 con prostaglandina e1 per il trattamento della disfunzione erettile
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000894A1 (en) * 1991-07-03 1993-01-21 Scott Nathan E Prostaglandin e2 treatment of impotence
US5510384A (en) * 1993-02-12 1996-04-23 Mckee; Rex N. Method of treating damaged mucosal and epithelial tissues with misoprostol

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4696821A (en) 1983-10-11 1987-09-29 Warner-Lambert Company Transdermal delivery system for administration of nitroglycerin
US5256652A (en) 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
ES2124225T3 (es) 1990-04-25 1999-02-01 Vivus Inc Tratamiento de la disfuncion erectil.
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5962528A (en) 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
US5252602A (en) * 1991-10-11 1993-10-12 Rafeul Alam Effects of misoprostol on allergic responses
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US6007836A (en) 1993-05-28 1999-12-28 Vericade, Inc. Transdermal vasodilator
FR2710649A1 (fr) 1993-09-30 1995-04-07 Germinal Sarl Film polymérique à base de prolamines, son procédé de préparation et ses applications .
EP0722323B1 (en) 1994-08-05 1999-09-22 Inpharma S.A. Compositions containing troxerutine complexed with phosphatidylcholine for topical treatment of erectile impotence
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
CN1126587A (zh) 1995-01-10 1996-07-17 王怀秀 经阴囊睾酮缓释系统
CA2215307A1 (en) 1995-03-14 1996-09-19 Vivus, Incorporated Pharmaceutical compositions and kits for preventing erectile dysfunction
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5688499A (en) 1996-03-13 1997-11-18 Queen's University At Kingston Antagonism of endothelin actions
US5684177A (en) 1996-05-17 1997-11-04 Torcan Chemical Ltd. Misoprostol
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
AU740758B2 (en) 1997-10-28 2001-11-15 Vivus, Inc. Treatment of female sexual dysfunction
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6277884B1 (en) 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
US5942545A (en) 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
WO2000032195A1 (fr) 1998-12-02 2000-06-08 Mochida Pharmaceutical Co., Ltd. Preparations destinees a etre administrees par voie uretrale
EP1108426A3 (en) 1999-12-02 2002-10-02 Pfizer Products Inc. Use of prostaglandin agonists to treat erectile dysfunction or impotence
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
EP1268000A4 (en) 2000-03-23 2004-12-29 Merck & Co Inc SPIROPIPERID DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS
EP1268449A4 (en) 2000-03-23 2004-09-15 Merck & Co Inc SUBSTITUTED PIPERIDINE AS MELANOCORTIN RECEPTOR AGONISTS
US6476037B1 (en) 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
EP1306087A4 (en) 2000-07-31 2007-07-25 Ono Pharmaceutical Co MEDICAMENT FOR TREATING EFFECTS OF DISORDER CONTAINING PROSTAGLANDINE DERIVATIVES AS ACTIVE COMPONENTS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000894A1 (en) * 1991-07-03 1993-01-21 Scott Nathan E Prostaglandin e2 treatment of impotence
US5510384A (en) * 1993-02-12 1996-04-23 Mckee; Rex N. Method of treating damaged mucosal and epithelial tissues with misoprostol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANON.: "Alprostadil for erectile impotence.", DRUG AND THERAP. BULL., vol. 33, no. 8, 1995, pages 61 - 62, XP002049460 *

Also Published As

Publication number Publication date
JP2001525803A (ja) 2001-12-11
EP0980245B1 (en) 2004-03-10
DE69822295T2 (de) 2005-02-24
US6210343B1 (en) 2001-04-03
DE69822295D1 (de) 2004-04-15
EP0980245A1 (en) 2000-02-23
WO1998050039A1 (en) 1998-11-12
ATE261307T1 (de) 2004-03-15
US6589990B1 (en) 2003-07-08
AU6848098A (en) 1998-11-27
ES2216279T3 (es) 2004-10-16
DE980245T1 (de) 2000-08-31
PT980245E (pt) 2004-06-30

Similar Documents

Publication Publication Date Title
BR0014652A (pt) Fabricação de conjugados de agente terapêutico-poliglutamato
MXPA03007712A (es) Sales farmaceuticas.
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
DE69906518D1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
PT934058E (pt) Forma estavel de medicamento para a administracao por via oral com derivados de benzimidazole como substancia activa e processo para a sua producao
MY125821A (en) Pharmaceutical composition of topiramate
IS1858B (is) Aðferð til að framleiða lyfjablöndu á formi smápilla til að meðhöndla þarmabólgur
DE58906926D1 (de) Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung.
AU1534699A (en) Osmotic dosage form comprising first and second coats
BR9712523A (pt) Novos derivados de pirazol heterociclilmetil-substituìdos
AU1227899A (en) Osmotic medicament releasing system
CA2093806A1 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
DE69820108D1 (de) Doppelkapsel zur verabreichung von arzneimitteln für vielfache therapien
BR9811086A (pt) Utilização de preparados de eritropoietina e ferro, processo para a produção de um preparado de combinação farmacêutica e embalagem unitária farmacêutica
EA199900734A1 (ru) Микрокапсулы, содержащие цис-платину
ES2191329T3 (es) Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares.
HU9502087D0 (en) Novel colon- or ileum-specific steroid derivatives
BR0008076A (pt) 16-hidroxiestratrienos como estrogênios de efeito seletivo
WO2000008007A3 (de) Cyclopentabenzofuran-derivate und ihre verwendung
ATE94401T1 (de) Physiologisch wirkende substanzen, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen davon.
FR2717081B1 (fr) Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro.
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
Fischer et al. Severe contact dermatitis due to nitroglycerin patches
BR0107881A (pt) Uso de fsh tratamento de infertilidade
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees

Effective date: 20121204